一类抗肿瘤新药洛铂治疗小细胞肺癌临床研究进展  

Clinical research progress of the new antitumor drug lobaplatin in the treatment of small cell lung cancer

作　　者：梁宇峰[1] 隋东虎[1] 程颖[2] 

机构地区：[1]贵州益佰制药股份有限公司医学部,贵阳550008 [2]吉林省肿瘤医院肺癌诊疗中心,长春130012

出　　处：《中国新药杂志》2014年第2期184-188,209,共6页Chinese Journal of New Drugs

基　　金：国家"重大新药创制"科技重大专项(2013ZX09104001)

摘　　要：洛铂是具有自主知识产权的国家一类抗肿瘤新药。大量临床研究表明,洛铂联合依托泊苷(EL)或伊立替康(IL)方案治疗小细胞肺癌的疗效与国际标准的顺铂联合依托泊苷(EP)方案相当,但安全性和耐受性更好,尤其适合老年和体质较弱患者,可作为一线治疗方案。其次,对于EP或卡铂联合依托泊苷(EC)方案一线治疗失败的复发性小细胞肺癌,IL方案疗效亦肯定,不良反应亦可耐受。含洛铂方案已成为小细胞肺癌治疗的新选择,有待进一步开展优化临床合理用药研究。Lobaplatin is a category I new antitumor drug with independent intellectual property rights.Compared with the cisplatin-based international standard regimens,a large number of clinical studies have shown that lobaplatin-based regimens have similar efficacy and better safety and tolerability.Especially it is suitable for old and weak patients,and can be used as a first-line therapy.Secondly,for the relapsed small cell lung cancer that failed to respond to the first-line treatment EP or EC regimens,IL regimen also has definite efficacy and good tolerability.It has been demonstrated that lobaplatin-based regimens have become the new treatment option of small cell lung cancer,but remain to be further studied to optimize clinical rational drug use.

关 键 词：洛铂 小细胞肺癌 临床研究 

分 类 号：R979.1[医药卫生—药品]